Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Enliven Therapeutics (ELVN)
NASDAQ:ELVN
Holding ELVN?
Track your performance easily
ELVN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$9.80 - $27.67
Previous Close$21.76
Volume112.39K
Average Volume (3M)249.81K
Market Cap
$1.10B
Enterprise Value$715.49M
Total Cash (Recent Filing)$312.39M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.98
Next Earnings
Nov 07, 2024EPS Estimate
-$0.51Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.93
Shares Outstanding47,237,207
10 Day Avg. Volume136,733
30 Day Avg. Volume249,808
Standard Deviation0.29
R-Squared0.03
Alpha-0.00371
Financial Highlights & Ratios
Price to Book (P/B)3.23
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-10.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-8.27
Forecast
1Y Price Target
$36.50Price Target Upside57.12% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Enliven Therapeutics News
Bulls Say, Bears Say
Bulls Say
Investor InterestMost attending investors seemed to be doing work on the story, indicating strong interest in the stock.
Market PotentialNuanced look at CML market shows it's not hard to get to $1-3Bn peak sales of ELVN-001 2L+.
Patient DynamicsPatients are switching from their 1L tyrosine kinase inhibitor (TKI) faster than previously expected, which could be due to better and more treatment options becoming available over the years.
Bears Say
Clinical TrialsAmong patients achieving major molecular response, most had already reached this milestone at the beginning of the trial.
Conflict Of InterestPotential conflict of interest might affect the objectivity of the firm's report.
Short InterestHigh short interest of 19.8% suggests many investors are betting against the stock.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ELVN FAQ
What was Enliven Therapeutics’s price range in the past 12 months?
Enliven Therapeutics lowest stock price was $9.80 and its highest was $27.67 in the past 12 months.
What is Enliven Therapeutics’s market cap?
Currently, no data Available
When is Enliven Therapeutics’s upcoming earnings report date?
Enliven Therapeutics’s upcoming earnings report date is Nov 07, 2024 which is in 48 days.
How were Enliven Therapeutics’s earnings last quarter?
Enliven Therapeutics released its earnings results on Aug 13, 2024. The company reported -$0.41 earnings per share for the quarter, beating the consensus estimate of -$0.55 by $0.14.
Is Enliven Therapeutics overvalued?
According to Wall Street analysts Enliven Therapeutics’s price is currently Undervalued.
Does Enliven Therapeutics pay dividends?
Enliven Therapeutics does not currently pay dividends.
What is Enliven Therapeutics’s EPS estimate?
Enliven Therapeutics’s EPS estimate is -$0.51.
How many shares outstanding does Enliven Therapeutics have?
Enliven Therapeutics has 47,237,206 shares outstanding.
What happened to Enliven Therapeutics’s price movement after its last earnings report?
Enliven Therapeutics reported an EPS of -$0.41 in its last earnings report, beating expectations of -$0.55. Following the earnings report the stock price went up 1.301%.
Which hedge fund is a major shareholder of Enliven Therapeutics?
Among the largest hedge funds holding Enliven Therapeutics’s share is Fairmount Funds Management Llc. It holds Enliven Therapeutics’s shares valued at 75M.
---
Enliven Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$36.50 (57.12% Upside)
$36.50 (57.12% Upside)
Blogger Sentiment
Bullish
ELVN Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 613.5K Shares
Last Quarter.
Last Quarter.
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
39.13%
12-Months-Change
Fundamentals
Return on Equity
-28.37%
Trailing 12-Months
Asset Growth
13.36%
Trailing 12-Months
Company Description
Enliven Therapeutics
Imara Inc is a clinical-stage biopharmaceutical company engaged in developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of haemoglobin.
---
ELVN Stock 12 Month Forecast
Average Price Target
$36.50
▲(57.12% Upside)
Technical Analysis
Best Analysts Covering ELVN
1 Year
1 Year Success Rate
6/12 ratings generated profit
1 Year Average Return
+26.54%
reiterated a buy rating last month
Copying Sam Slutsky's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +26.54% per trade.
---